



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |   |
|---|-----------|---|
| <b>(51) International Patent Classification <sup>5</sup> :</b><br>A61K 31/70, 39/12, C12N 7/00, 15/00,<br>C12P 21/06, C12Q 1/70, G01N 33/531  | <b>A1</b> | <b>(11) International Publication Number:</b> WO 94/17810<br><b>(43) International Publication Date:</b> 18 August 1994 (18.08.94)  |
| <b>(21) International Application Number:</b> PCT/US94/02107<br><b>(22) International Filing Date:</b> 10 February 1994 (10.02.94)<br><br><b>(30) Priority Data:</b><br>08/017,130      12 February 1993 (12.02.93)      US<br><br><b>(71) Applicant:</b> THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY [US/US]; 36th and Spruce Streets, Philadelphia, PA 19104 (US).<br><br><b>(72) Inventors:</b> PLOTKIN, Stanley, A.; 29, rue du Général-Delestraint, F-75016 Paris (FR). RICCIARDI, Robert, P.; 137 W. Forge Road, Glen Mills, PA 19342 (US). GONCZOL, Eva; Radnor House, Apartment 916, 1030 E. Lancaster Avenue, Rosemont, PA 19010 (US).<br><br><b>(74) Agents:</b> BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US). |           | <b>(81) Designated States:</b> CA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).<br><br><b>Published</b><br><i>With international search report.<br/>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| <b>(54) Title:</b> RECOMBINANT CYTOMEGALOVIRUS VACCINE<br><br><b>(57) Abstract</b><br><br>The present invention provides a non-defective adenovirus recombinant expression system for the expression of immediate-early exon 4 proteins, said recombinant HCMV-expressing adenovirus being useful as an immunogenic composition and vaccine.  |           |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                            | TD | Chad                     |
| CS | Czechoslovakia           | LV | Latvia                                | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | US | United States of America |
| FI | Finland                  | MN | Mongolia                              | UZ | Uzbekistan               |
| FR | France                   |    |                                       | VN | Viet Nam                 |
| GA | Gabon                    |    |                                       |    |                          |

## RECOMBINANT CYTOMEGALOVIRUS VACCINE

This work was performed with government support under National Institutes of Health grants AI-07278 and  
5 HD-18957. The U.S. government has certain rights in this invention.

### Field of the Invention

The present invention refers generally to a  
10 recombinant human cytomegalovirus vaccine, and more specifically to a subunit vaccine.

### Background of the Invention

Cytomegalovirus (CMV) is one of a group of  
15 highly host specific herpes viruses that produce unique large cells bearing intranuclear inclusions. The envelope of the human cytomegalovirus (HCMV) is characterized by a major glycoprotein complex recently termed gB or gCI, which was previously referred to as gA.  
20 HCMV causes cytomegalic inclusion disease and has been associated with a syndrome resembling infectious mononucleosis in adults. It also induces complications in immunocompromised individuals.

CMV infection *in utero* is an important cause of  
25 central nervous system damage in newborns. Although the virus is widely distributed in the population, about 40% of women enter pregnancy without antibodies and thus are susceptible to infection. About 1% of these women undergo primary infection *in utero*. Classical  
30 cytomegalic inclusion disease is rare; however, a proportion of the infected infants, including those who were symptom free, are subsequently found to be mentally retarded.

Preliminary estimates based on surveys of  
35 approximately 4,000 newborns from several geographical areas indicate that the virus causes significant damage

of the central nervous system leading to mental deficiency in at least 10%, and perhaps as high as 25%, of infected infants. Assuming that about 1% of newborn infants per year excrete CMV and that about one fourth of those develop mental deficiency, in the United States this means approximately 10,000 brain-damaged children born per year. This is a formidable number, particularly in view of the ability of these children to survive [J. Infect. Dis., 123 (5):555 (1971)].

10 HCMV in humans has also been observed to cause serious complications and infections in the course of organ transplantations, especially with kidney and liver transplants.

Several HCMV vaccines have been developed or are in the process of development. Vaccines based on live attenuated strains of HCMV have been described. [See, e.g., S. A. Plotkin et al, Lancet, 1:528-30 (1984); S. A. Plotkin et al, J. Infect. Dis., 134:470-75 (1976); S. A. Plotkin et al, "Prevention of Cytomegalovirus Disease by Towne Strain Live Attenuated Vaccine", in Birth Defects, Original Article Series, 20(1):271-287 (1984); J. P. Glazer et al, Ann. Intern. Med., 91:676-83 (1979); and U. S. Patent 3,959,466.] A proposed HCMV vaccine using a recombinant vaccinia virus expressing HCMV glycoprotein B has also been described. [See, e.g., Cranage, M. P. et al, EMBO J., 5:3057-3063 (1986).] However, vaccinia models for vaccine delivery are believed to cause local reactions. Additionally, vaccinia vaccines are considered possible causes of encephalitis.

30 Adenoviruses have been developed previously as efficient heterologous gene expression vectors. For example, an adenovirus vector has been employed to express herpes simplex virus glycoprotein gB [D. C. Johnson et al, Virology, 164:1-14 (1988)]; human

immunodeficiency virus type 1 envelope protein [R. L. Dewar et al, J. Virol., 63:129-136 (1988)]; and hepatitis B surface antigen [A. R. Davis et al, Proc. Natl. Acad. Sci., U.S.A., 82:7560-7564 (1985); J. E. Morin et al, Proc. Natl. Acad. Sci., U.S.A., 84:4626-4630 (1987)].  
Adenoviruses have also been found to be non-toxic as vaccine components in humans [See, e.g., E. T. Takajui et al, J. Infect. Dis., 140:48-53 (1970); P. B. Collis et al, J. Inf. Dis., 128:74-750 (1973); and R. B. Couch et al, Am. Rev. Respir. Dis., 88:394-403 (1963)].

There remains a need in the art for additional vaccines capable of preventing CMV infection by generating neutralizing antibody and cellular responses to CMV in the human immune system.

#### Summary of the Invention

In one aspect, the present invention provides a non-defective recombinant adenovirus containing an immediate-early exon-4 (IE-exon-4) subunit of the HCMV free from association with any additional human proteinaceous material. In this recombinant adenovirus, the HCMV subunit is under the control of regulatory sequences capable of expressing the IE-exon 4 subunit in vitro and in vivo.

Another aspect of the present invention is a vaccine composition comprising a non-defective recombinant adenovirus, as described above.

In a further aspect, the invention provides a method of using the recombinant adenovirus containing the subunit gene encoding IE-exon-4, in the manufacture of a vaccine composition useful against HCMV infection. The inventors have found that presenting these HCMV subunit proteins expressed by in vivo transcription of the gene to a vaccinate is particularly capable of eliciting a protective immune response.

In yet a further aspect the invention provides an adenovirus-produced HCMV IE-exon-4 subunit, which subunit may also form vaccine compositions to protect humans against HCMV.

5 In still a further aspect, the present invention provides a novel murine model useful for demonstrating cytotoxic T lymphocyte (CTL) response to individual HCMV proteins.

10 Other aspects and advantages of the present invention are described further in the following detailed description of preferred embodiments of the present invention.

#### Detailed Description of the Invention

15 The present invention provides novel immunogens and vaccine components for HCMV which comprise an adenovirus expression system capable of expressing a selected HCMV subunit gene *in vivo*. Alternatively the selected subunit for use in an immunogenic composition, 20 i.e., a composition which elicits a humoral and/or a cell-mediated immune response, may be expressed in, and isolated from, the recombinant adenovirus expression system. Such an immunogenic composition may be used in a vaccine for protecting against human CMV infection.

25 As provided by the present invention, any adenovirus strain capable of replicating in mammalian cells *in vitro* may be used to construct an expression vector for the selected HCMV subunit. However, a preferred expression system involves a non-defective 30 adenovirus strain, including, but not limited to, adenovirus type 5. Alternatively, other desirable adenovirus strains may be employed which are capable of being orally administered, for use in expressing the CMV subunit *in vivo*. Such strains useful for *in vivo* 35 production of the subunit in addition to adenovirus-5

strains include adenovirus type 4, 7, and 21 strains. [See, e.g., Takajuji et al, cited above]. Appropriate strains of adenovirus, including those identified above and those employed in the examples below are publicly  
5 available from sources such as the American Type Culture Collection, Rockville, Maryland.

The presently preferred subunit protein for use in the present invention is the HCMV IE-exon 4 subunit. The full length IE1 gene was reported by Stenberg et al,  
10 J. Virol., 49:190-199 (1984). An XbaI E fragment containing the exon 4 subunit of the IE (or IE1) gene of the Towne strain of HCMV was reported to GenBank, Los Alamos, New Mexico in September 15, 1989 by Stenberg et al. The nucleic acid sequences of the coding region of  
15 the IE-exon-4 are provided in SEQ ID NO:1, in which the native TC nucleotides which precede the lysine codon have been modified to the ATG initiation codon. SEQ ID NO:2 provides amino acid sequences of the IE-exon 4 protein.

In the practice of one embodiment of this  
20 invention the HCMV IE-exon 4 subunit may be produced in vitro by recombinant techniques in large quantities sufficient for use in a subunit vaccine. Alternatively, more than one HCMV subunit may be employed in a vaccine according to the teachings of the present invention.

25 Alternatively, the recombinant adenovirus containing the subunit may itself be employed as an immunogen or vaccine component, capable of expressing the subunit in vivo. One embodiment of the invention provides a replication competent adenovirus-5 vector  
30 carrying the HCMV IE-exon 4 gene.

The desired subunit may be isolated from an available strain of HCMV for insertion into the selected adenovirus. A number of strains of human CMV have been isolated. For example, the Towne strain of CMV, a  
35 preferred strain for use in preparation of a vaccine of

this invention because of its broad antigenic spectrum and its attenuation, was isolated from the urine of a two month old male infant with cytomegalic inclusion disease (symptoms - central nervous system damage and  
5 hepatosplenomegaly). This strain of CMV was isolated by Stanley A. Plotkin, M.D. of The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania, and is described in J. Virol., 11 (6): 991 (1973). This strain is freely available from The Wistar Institute or from the  
10 American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, USA, under accession number VR-977. However, other strains of CMV useful in the practice of this invention may be obtained from depositories like the ATCC or from other institutes or  
15 universities.

In addition to isolating the desired IE-exon 4 subunit from an available strain of HCMV for insertion into the selected adenovirus, the subunit sequence can be chemically synthesized by resort to conventional methods  
20 known to one of skill in the art and, e.g., SEQ ID NOS: 1 and 2. Alternatively, the sequence may be purchased from commercial sources.

The recombinant adenovirus of the present invention may also contain multiple copies of the HCMV  
25 subunit. Alternatively, the recombinant virus may contain more than one HCMV subunit type, so that the virus may express two or more HCMV subunits or immediate early antigens and subunits together. The sequences of other HCMV subunits of two HCMV strains have been  
30 published [See, e.g., Mach et al, J. Gen. Virol., 67:1461-1467 (1986); Cranage et al, (1986) cited above; and Spaete et al, Virol., 167:207-225 (1987)].

In the construction of the adenovirus vector of the present invention, the CMV subunit sequence is  
35 preferably inserted in an adenovirus strain under the



control of an expression control sequence in the virus itself. The adenovirus vector of the present invention preferably contains other sequences of interest in addition to the HCMV subunit. Such sequences may include  
5 regulatory sequences, enhancers, suitable promoters, secretory signal sequences and the like. The techniques employed to insert the subunit sequence into the adenovirus vector and make other alterations in the viral DNA, e.g., to insert linker sequences and the like, are  
10 known to one of skill in the art. See, e.g., T. Maniatis et al, "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982). Thus, given the disclosures contained herein the construction of suitable adenovirus expression vectors  
15 for expression of an HCMV IE-exon 4 subunit protein is within the skill of the art. Example 1 below describes in detail the construction of a non-defective adenovirus containing the HCMV IE-exon-4 subunit.

The recombinant adenovirus itself, constructed  
20 as described above, may be used directly as an immunogen or a vaccine component. According to this embodiment of the invention, the recombinant adenovirus, containing the HCMV subunit, e.g., the IE-exon-4 subunit, is introduced directly into the patient by vaccination. The  
25 recombinant virus, when introduced into a patient directly, infects the patient's cells and produces the CMV subunit in the patient's cells. The inventors have found that this method of presenting these HCMV genes to a vaccinee is particularly capable of eliciting a  
30 protective immune response. Examples 2 and 3 below demonstrate the ability of the adenovirus recombinant of this invention, Ad-IE, containing subunit IE-exon-4 to elicit a CTL response from immunized mice.

According to another embodiment of this  
35 invention, once the recombinant viral vector containing

the CMV subunit protein, e.g., the IE-exon 4 subunit, is constructed, it may be infected into a suitable host cell for *in vitro* expression. The infection of the recombinant viral vector is performed in a conventional manner. [See, Maniatis et al, supra.] Suitable host cells include mammalian cells or cell lines, e.g., A549 (human lung carcinoma) or 293 (transformed human embryonic kidney) cells.

The host cell, once infected with the recombinant virus of the present invention, is then cultured in a suitable medium, such as Minimal Essential Medium (MEM) for mammalian cells. The culture conditions are conventional for the host cell and allow the subunit, e.g., IE-exon4, to be produced either intracellularly, or secreted extracellularly into the medium. Conventional protein isolation techniques are employed to isolate the expressed subunit from the selected host cell or medium.

When expressed *in vitro* and isolated from culture, the subunit, e.g., IE-exon4, may then be formulated into an appropriate vaccine composition. Such compositions may generally contain one or more of the recombinant CMV subunits.

The preparation of a pharmaceutically acceptable vaccine composition, having appropriate pH, isotonicity, stability and other conventional characteristics is within the skill of the art. Thus, such vaccines may optionally contain other components, such as adjuvants and/or carriers, e.g., aqueous suspensions of aluminum and magnesium hydroxides.

Thus, the present invention also includes a method of vaccinating humans against human CMV infection with the recombinant adenovirus vaccine composition. This vaccine composition is preferably orally administered, because adenoviruses are known to replicate in cells of the stomach. Previous studies with

adenoviruses have shown them to be safe when administered orally [see, e.g., Collis et al, cited above]. However, the present invention is not limited by the route of administration selected for the vaccine.

5           When the recombinant adenovirus is administered as the vaccine, a dosage of between  $10^5$  and  $10^8$  plaque forming units may be used. Additional doses of the vaccines of this invention may also be administered where considered desirable by the physician. The dosage  
10 regimen involved in the method for vaccination against CMV infection with the recombinant virus of the present invention can be determined considering various clinical and environmental factors known to affect vaccine administration.

15           Alternatively, the vaccine composition may comprise one or more recombinantly-produced human CMV subunit proteins, preferably including the IE-exon-4 subunit. The *in vitro* produced subunit proteins may be introduced into the patient in a vaccine composition as  
20 described above, preferably employing the oral, nasal or subcutaneous routes of administration. The presence of the subunit produced either *in vivo* or as part of an *in vitro* expressed subunit administered with a carrier, stimulates an immune response in the patient. Such an  
25 immune response is capable of providing protection against exposure to the whole human CMV microorganism. The dosage for all routes of administration of the *in vitro* vaccine containing one or more of the CMV subunit proteins is generally greater than 20 micrograms of  
30 protein per kg of patient body weight, and preferably between 40 and 80 micrograms of protein per kilogram.

          The utility of the recombinant adenoviruses of the present invention is demonstrated through the use of a novel mouse experimental model which characterizes  
35 cytotoxic T lymphocyte (CTL) responses to individual

proteins of strictly human-restricted viruses. For example, the model as used herein is based on the use of two types of recombinant viruses, an adenovirus and a canarypox virus, both expressing a gene of the same HCMV protein. This model is useful in identifying immunodominant HCMV proteins and immunodominant epitopes of individual proteins to incorporate into an appropriate immunizing vector, analysis of proteins of various HCMV strains, immunization protocols and the longevity of cell-mediated immunity to individual proteins or epitopes; and investigation of the optimal vector for effective introduction of a certain antigen or epitope to the host immune system.

According to this model, mice are immunized with one recombinant, such as that of the invention, and CTL activity tested in target cells infected with the other recombinant. Specifically, Example 2 below provides a murine model of the cytotoxic T lymphocyte (CTL) response to the glycoprotein B (gB) gene of human cytomegalovirus (HCMV) based on the use of gB-expressing adenovirus (Ad-gB) and several poxvirus recombinants.

The following examples illustrate the construction of a non-defective adenovirus strain capable of expressing the HCMV IE-exon-4, and the efficacy of this composition as an HCMV vaccine. These examples are illustrative only and do not limit the scope of the present invention.

#### Example 1 - Construction of Ad-IE exon-4 recombinant virus

The protection of humans from CMV infection or virus-induced diseases is based on antibody dependent and/or T-cell dependent immune responses. The following experimental data demonstrates that an adenovirus recombinant containing the major immediate early (IE)

gene of HCMV elicits a protective immune response in mice. The nucleic acid sequences of the coding region of the IE-exon-4 are provided in SEQ ID NO:1, in which the native TC nucleotides which precede the lysine codon have  
5 been modified to the ATG initiation codon.

To construct the IE-exon-4 adenovirus recombinant, the polymerase chain reaction (PCR) technique was used to amplify the exon 4 portion of the IE gene from purified HCMV genomic DNA (Towne strain).  
10 The PCR primers were synthesized so as to incorporate the proper restriction endonuclease cleavage site, XbaI, (underlined in SEQ ID NOS: 3 and 4 below) for insertion into the XbaI site of the adenovirus vector. In addition, the 5' primer was also modified so that an ATG  
15 start translation codon was inserted at the first amino acid position of exon 4. The oligonucleotides used as primers were the following:

5' IE-exon 4: SEQ ID NO:3:

5'-TTATCCTCC TCTAGA ATGAAACAGATTAAG

20 3' IE-exon 4: SEQ ID NO:4:

5'-ATATATATAT TCTAGA GTTTACTGGTCGAC

The 5' oligonucleotide corresponds to nucleotide positions 1 to 27 (sense orientation) and the 3' oligonucleotide corresponds to nucleotide positions 1251 to 1222 (anti-sense orientation) of an XbaI E fragment of  
25 the HCMV IE1 gene (Towne strain) available from GenBank, Los Alamos, New Mexico (Accession #M11630, Code #8SMIE4). This fragment was used as an Exon 4 gene template for the PCR reaction. The full length IE1 gene was reported by  
30 Stenberg et al, J. Virol., 49:190-199 (1984).

In order to clone the IE1 exon 4, the 5' and 3' primers (400 ng each) were mixed with 0.1 µg of purified HCMV genomic DNA and the DNA was amplified using the Perkin-Elmer amplitaq kit. The final reaction volume was  
35 100 µl and the thermocycling conditions were 94°C, 1 min;

52°C, 1 min; 72°C, 1 min, repeated for a total of 35 cycles. Amplified DNA was purified by cutting the proper size DNA fragment out of a 1.2% agarose gel, digested with XbaI, repurified by cutting the digested fragments out of a 1.2% agarose gel and then ligated into the XbaI site of the cloning vector pAd-5. Positive recombinants were verified by DNA sequence analysis. Sequence analysis confirmed the orientation of the clones since the XbaI digested DNA fragments could be inserted into the adenovirus vector in two different orientations.

In this construct the E3 coding region (between map units 78.5 and 84.0) of the adenovirus is replaced by the exon-4 fragment. The correct orientation allows for the proper transcription of the gene fragment (in the sense orientation) from the adenovirus E3 promoter.

The exon-4 product of the HCMV-IE gene was shown to be a target for CD8 cytotoxic and CD4 lymphoproliferative T cell responses in humans. The Ad-IE-exon-4 construct is non-defective in replication (i.e., capable of replicating normally) in tissue culture cells.

This Ad-IE-exon-4 recombinant was used in the *in vitro* cytotoxic T lymphocyte (CTL) assay and mouse model described below.

#### Example 2 - CTL Assay-Murine Model

This CTL assay is a system in which two types of viral expression vectors, poxvirus and adenovirus, carrying the same HCMV IE-exon 4 subunit gene, are alternately used for immunization of animal or for infection of target cells to show that HCMV IE-exon 4 subunit is an inducer of CTL in mice. Using this model system, the relative immunogenicities of both a gB antigen expressed by different recombinant viruses and the IE exon 4 subunit antigen has been evaluated.

#### A. Recombinant Viruses Used in CTL Assays

The following recombinant viruses were used in the CTL assay of Example 3 below to demonstrate the vaccine utility of the recombinant adenoviruses of the present invention.

Wild-type human adenovirus type 5 (WT-Ad) and the non-defective adenovirus-gB recombinant (Ad-gB) (prepared as described in European Patent Publication No. 389,286 (Sept. 26, 1990) and G. S. Marshall et al, J. Infect. Dis., 162:1177-1181 (1990)) were propagated in human lung carcinoma A549 cells [ATCC CCL185], using standard procedures.

An E3-deleted adenovirus type 5 mutant lacking the XbaI D fragment of adenovirus DNA (Ad5ΔE3) was constructed by overlap recombination, using plasmid pAd-5 mu 59.5-100, which was deleted in E3 sequences (mu 78.5-84) using the techniques described in EP No. 389,286 and Marshall et al, cited above, and pAd-5 mu 0-75.9.

A vaccinia virus recombinant containing the gB subunits (VacC-gB) described previously in Gonczol et al, Vaccine, 9:631-637 (1991) and the parental Copenhagen strain of vaccinia, VC-2 (also known as wild-type vaccinia (WT-Vac)) were grown in Vero cells [E. Gonczol et al, Vaccine, 8:130-136 (1990); J. Tartaglia et al, Crit. Rev. Immunol., 10:13-30 (1990)].

The vaccinia WR strain [obtained from Dr. Enzo Paoletti, Virogenetics Corp, Troy, NY] was used to develop a recombinant expressing HCMV-gB ((VacW)-gB). This recombinant was derived using a strategy similar to that described for the VacC-gB recombinant (Gonczol et al., cited above).

A canarypox recombinant [ALVAC-CMV (vCP139) which is subsequently referred to as Cp-gB] expressing the HCMV-gB gene was constructed using a strategy similar to that described for a canarypox-rabies recombinant in

Taylor et al., Vaccine, 9:190-193 (1991) [also obtained from Dr. Enzo Paoletti]. Briefly, the gene encoding the HCMV (Towne strain) glycoprotein B was inserted into a canarypox donor plasmid consisting of a polylinker  
5 flanked by genomic sequence from which a nonessential gene was specifically deleted (at a unique EcoRI site within a 3.3 kbp PvuII subgenomic fragment of canarypox DNA). Expression of the gB protein gene was placed under the transcriptional control of an early/late vaccinia  
10 virus promoter (H6) previously described [Percus et al., J. Virol., 63:3829-3835 (1989)]. Cp-gB was derived and plaque-purified by standard methods [Panicali and Paoletti, Proc. Natl. Acad. Sci. USA, 79:4927-4931 (1982)]. The Cp-gB recombinant and parental canarypox  
15 virus (WT-Cp) were propagated on primary chick embryo fibroblasts (CEF) cells [ATCC CRL 1590].

B. CTL Response of Ad-gB Recombinant

For immunization of mice, Ad-gB and WT-Ad were purified by CsCl gradient centrifugation. VacC-gB,  
20 VacW-gB and WT-Vac were purified by sucrose gradient centrifugation, and Cp-gB and WT-Cp were concentrated on sucrose cushion.

Six- to 8-week-old female BALB/c and CBA mice (from Harlan Sprague-Dawley and Jackson) and 12-week-old  
25 male BALB/k mice (from The Wistar Institute Animal Facility) were immunized intraperitoneally (i.p.) with the recombinant viruses described above at  $1-5 \times 10^8$  pfu unless otherwise stated.

One to 12 weeks later, spleens were aseptically  
30 removed and cell suspensions were prepared by gently pressing the spleens through a stainless steel mesh. Cells were suspended at  $2.5 \times 10^6$  viable cells/ml in RPMI 1640 medium containing 5% FBS (Gibco),  $2 \times 10^{-5}$  M 2-mercaptoethanol, 14 mM HEPES buffer, glutamine and 50  
35  $\mu$ g/ml gentamicin. Spleen cell cultures were restimulated



in vitro with Ad-gB (multiplicity of infection (m.o.i.) = 10) or VacC-gB (m.o.i. = 0.5 ) infected autologous spleen cells for 5 days in 24-well plates. Cytolytic activity of nonadherent spleen cells was tested in a chromium release assay which was performed as follows.

(1) T-cell subset depletion

For in vitro depletion of CD4 or CD8 cells,  $3 \times 10^6$  spleen cells were incubated with anti-mouse CD4 monoclonal antibody (MAb) [Pharmlngen; Cat.3:01061 D; 20  $\mu\text{g}/3 \times 10^6$  cells] or CD8 MAb [Accurate; Cat. #:CL-8921; diluted 1:4] for 60 minutes at 4°C, and further incubated in the presence of rabbit complement [Accurate; Low-tox M; diluted 1:10] for 30 minutes at 37°C. The cells were washed twice and used as effector cells in a  $^{51}\text{Cr}$ -release test.

(2) Chromium release assay

P815 (H-2<sup>d</sup>) [ATCC TIB 64], mouse MC57 (H-2<sup>b</sup>) cells [also termed MC-57G, D.P. Aden et al, Immunogenetics, 3:209-221 (1976)] and mouse NCTC clone 929 (H-2<sup>k</sup>) cells [ATCC CCL 1] were used as target cells. The HCMV neutralization titer of mouse sera was determined on MRC-5 cells [ATCC CCL 171] by the microneutralization method as described in Gonczol et al., J. Virol. Methods, 14:37-41 (1986).

The target cells were infected with Ad-gB or Ad-5ΔE3 (multiplicity of infection (m.o.i.) = 40-80, 40 hours) or with Vac-gB or WT-Vac (m.o.i. = 5-10, 4 hours). Target cells were washed in the modified RPMI 1640 medium described above and  $2 \times 10^6$  cells were labeled with 100  $\mu\text{Ci}$  of [ $^{51}\text{Cr}$ ]NaCrO<sub>4</sub> [Amersham, specific activity 250-500 mCi/mg] for 1 hour. The labeled target cells were washed 3 times in phosphate-buffered saline (PBS) and then mixed with the effector cells at various effector:target ratios in triplicate using 96-well U-bottomed microtiter plates and incubated for 4 hours.

Percentage specific  $^{51}\text{Cr}$  release was calculated as:  $[(\text{cpm experimental release} - \text{cpm spontaneous release}) / (\text{cpm maximal release} - \text{cpm spontaneous release})] \times 100$ . Standard deviation of the mean of triplicate cultures was less than 10%, and spontaneous release was always less than 25%.

C. CTL Response of Ad-IE exon-4 recombinant

The CTL-assay was carried out as described above for gB. In this CTL assay mice were immunized with Ad-IE-exon-4 recombinant virus and target cells were infected with Vac(WR strain)-IE recombinant virus or parental vaccinia virus. Briefly, mice were immunized i.p. with Ad-IE-exon-4 at  $1-2 \times 10^8$  plaque forming units (p.f.u). These spleen cell cultures were restimulated in vitro with Ad-IE-exon-4 or Vaccinia (Copenhagen strain)-IE-exon-4 (Vac-IE-exon-4)-infected autologous spleen cells for 5 days. Cytolytic activity of non-adherent spleen cells was tested in a chromium release assay. The vaccinia recombinants were provided by Dr. Paoletti, Virogenetics Corporation, Troy, New York.

For the chromium release assay, MHC class-I matched and mismatched target cells were infected with Ad-IE-exon-4, or parental adenovirus, or with Vac-IE-exon-4 or parental vaccinia virus. Percentage specific  $^{31}\text{chromium}$  release was calculated as  $[(\text{cpm experimental release} - \text{cpm spontaneous release}) / (\text{cpm maximal release} - \text{cpm spontaneous release})] \times 100$ .

When tested in the CTL assay described above, the CBA mice immunized with the Ad-IE-exon-4 recombinant developed a HCMV-IE-exon-4 specific cytotoxic T cell response.

Example 3 - Protection Study using Ad-IE exon-4

HCMV-protein-specific protection was demonstrated in Ad-HCMV immunized mice from a vaccinia-

HCMV recombinant-induced encephalitis/meningitis and death, as follows. The model is described above.

In this experiment, CBA mice were immunized i.p. with  $2 \times 10^8$  p.f.u. of the Ad-HCMV subunit protein recombinant virus, e.g. Ad-IE-exon 4 of Example 1, and 5-18 days later were challenged intracerebrally (i.c.) with a lethal dose of a vaccinia(WR strain)-HCMV recombinant virus (e.g. Vac(WR)-gB). Vaccinia(WR strain)-IE or vaccinia(WR strain)-gB recombinant viruses were obtained from Dr. Paoletti, Virogenetics Corporation, Troy, NY. The WR-strain of vaccinia is neurovirulent for mice.

When tested in this mouse model, CBA mice immunized with the Ad-IE-exon-4 recombinant were protected against a lethal dose of vaccinia WR-IE recombinant virus. The protection was HCMV-IE protein specific. Ninety percent of CBA mice, immunized i.p. with Ad-IE-exon-4 recombinant virus were protected against a lethal dose of Vac(WR-strain)-IE recombinant virus, inoculated intracerebrally. Control mice, immunized with Ad-gB recombinant virus or parental adenovirus and challenged later with the Vac(WR)-IE recombinant, died within 7 days after challenge, demonstrating that protection was IE-exon-4 protein specific.

Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. For example, use of other appropriate non-defective adenovirus strains for construction of analogous expression systems to express the HCMV IE-exon-4 gene may be constructed according to the disclosure of the present invention. Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

18

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: The Wistar Institute of Anatomy and  
Biology

(ii) TITLE OF INVENTION: Recombinant Cytomegalovirus  
Vaccine

(iii) NUMBER OF SEQUENCES: 4

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Howson and Howson  
(B) STREET: Spring House Corporate Cntr,  
PO Box 457  
(C) CITY: Spring House  
(D) STATE: Pennsylvania  
(E) COUNTRY: USA  
(F) ZIP: 19477

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0,  
Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/017,130  
(B) FILING DATE: 12-FEB-1993

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Bak, Mary E.  
(B) REGISTRATION NUMBER: 31,215  
(C) REFERENCE/DOCKET NUMBER: WST6BPCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 215-540-9200  
(B) TELEFAX: 215-540-5818

19

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1221 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1218

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ATG | AAA | CAG | ATT | AAG | GTT | CGA | GTG | GAC | ATG | CTG | CGG | CAT | 39  |
| Met | Lys | Gln | Ile | Lys | Val | Arg | Val | Asp | Met | Leu | Arg | His |     |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     |
| AGA | ATC | AAG | GAG | CAC | ATG | CTG | AAA | AAA | TAT | ACC | CAG | ACG | 78  |
| Arg | Ile | Lys | Glu | His | Met | Leu | Lys | Lys | Tyr | Thr | Gln | Thr |     |
|     | 15  |     |     |     |     | 20  |     |     |     |     | 25  |     |     |
| GAA | GAG | AAA | TTC | ACT | GGC | GCC | TTT | AAT | ATG | ATG | GGA | GGA | 117 |
| Glu | Glu | Lys | Phe | Thr | Gly | Ala | Phe | Asn | Met | Met | Gly | Gly |     |
|     |     |     | 30  |     |     |     |     | 35  |     |     |     |     |     |
| TGT | TTG | CAG | AAT | GCC | TTA | GAT | ATC | TTA | GAT | AAG | GTT | CAT | 156 |
| Cys | Leu | Gln | Asn | Ala | Leu | Asp | Ile | Leu | Asp | Lys | Val | His |     |
|     | 40  |     |     |     | 45  |     |     |     |     | 50  |     |     |     |
| GAG | CCT | TTC | GAG | GAG | ATG | AAG | TGT | ATT | GGG | CTA | ACT | ATG | 195 |
| Glu | Pro | Phe | Glu | Glu | Met | Lys | Cys | Ile | Gly | Leu | Thr | Met |     |
|     |     | 55  |     |     |     |     | 60  |     |     |     |     | 65  |     |
| CAG | AGC | ATG | TAT | GAG | AAC | TAC | ATT | GTA | CCT | GAG | GAT | AAG | 234 |
| Gln | Ser | Met | Tyr | Glu | Asn | Tyr | Ile | Val | Pro | Glu | Asp | Lys |     |
|     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     |
| CGG | GAG | ATG | TGG | ATG | GCT | TGT | ATT | AAG | GAG | CTG | CAT | GAT | 273 |
| Arg | Glu | Met | Trp | Met | Ala | Cys | Ile | Lys | Glu | Leu | His | Asp |     |
|     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |     |     |
| GTG | AGC | AAG | GGC | GCC | GCT | AAC | AAG | TTG | GGG | GGT | GCA | CTG | 312 |
| Val | Ser | Lys | Gly | Ala | Ala | Asn | Lys | Leu | Gly | Gly | Ala | Leu |     |
|     |     |     | 95  |     |     |     |     | 100 |     |     |     |     |     |
| CAG | GCT | AAG | GCC | CGT | GCT | AAA | AAG | GAT | GAA | CTT | AGG | AGA | 351 |
| Gln | Ala | Lys | Ala | Arg | Ala | Lys | Lys | Asp | Glu | Leu | Arg | Arg |     |
| 105 |     |     |     |     | 110 |     |     |     |     | 115 |     |     |     |

20

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| AAG | ATG | ATG | TAT | ATG | TGC | TAC | AGG | AAT | ATA | GAG | TTC | TTT | 390 |
| Lys | Met | Met | Tyr | Met | Cys | Tyr | Arg | Asn | Ile | Glu | Phe | Phe |     |
|     |     | 120 |     |     |     |     | 125 |     |     |     |     | 130 |     |
| ACC | AAG | AAC | TCA | GCC | TTC | CCT | AAG | ACC | ACC | AAT | GGC | TGC | 429 |
| Thr | Lys | Asn | Ser | Ala | Phe | Pro | Lys | Thr | Thr | Asn | Gly | Cys |     |
|     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| AGT | CAG | GCC | ATG | GCG | GCA | TTG | CAG | AAC | TTG | CCT | CAG | TGC | 468 |
| Ser | Gln | Ala | Met | Ala | Ala | Leu | Gln | Asn | Leu | Pro | Gln | Cys |     |
|     | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |
| TCC | CCT | GAT | GAG | ATT | ATG | GCT | TAT | GCC | CAG | AAA | ATA | TTT | 507 |
| Ser | Pro | Asp | Glu | Ile | Met | Ala | Tyr | Ala | Gln | Lys | Ile | Phe |     |
|     |     |     | 160 |     |     |     |     | 165 |     |     |     |     |     |
| AAG | ATT | TTG | GAT | GAG | GAG | AGA | GAC | AAG | GTG | CTC | ACG | CAC | 546 |
| Lys | Ile | Leu | Asp | Glu | Glu | Arg | Asp | Lys | Val | Leu | Thr | His |     |
| 170 |     |     |     |     | 175 |     |     |     |     | 180 |     |     |     |
| ATT | GAT | CAC | ATA | TTT | ATG | GAT | ATC | CTC | ACT | ACA | TGT | GTG | 585 |
| Ile | Asp | His | Ile | Phe | Met | Asp | Ile | Leu | Thr | Thr | Cys | Val |     |
|     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |     |
| GAA | ACA | ATG | TGT | AAT | GAG | TAC | AAG | GTC | ACT | AGT | GAC | GCT | 624 |
| Glu | Thr | Met | Cys | Asn | Glu | Tyr | Lys | Val | Thr | Ser | Asp | Ala |     |
|     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     |
| TGT | ATG | ATG | ACC | ATG | TAC | GGG | GGC | ATC | TCT | CTC | TTA | AGT | 663 |
| Cys | Met | Met | Thr | Met | Tyr | Gly | Gly | Ile | Ser | Leu | Leu | Ser |     |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |
| GAG | TTC | TGT | CGG | GTG | CTG | TCC | TGC | TAT | GTC | TTA | GAG | GAG | 702 |
| Glu | Phe | Cys | Arg | Val | Leu | Ser | Cys | Tyr | Val | Leu | Glu | Glu |     |
|     |     |     | 225 |     |     |     |     | 230 |     |     |     |     |     |
| ACT | AGT | GTG | ATG | CTG | GCC | AAG | CGG | CCT | CTG | ATA | ACC | AAG | 741 |
| Thr | Ser | Val | Met | Leu | Ala | Lys | Arg | Pro | Leu | Ile | Thr | Lys |     |
| 235 |     |     |     |     | 240 |     |     |     |     | 245 |     |     |     |
| CCT | GAG | GTT | ATC | AGT | GTA | ATG | AAG | CGC | CGC | ATT | GAG | GAG | 780 |
| Pro | Glu | Val | Ile | Ser | Val | Met | Lys | Arg | Arg | Ile | Glu | Glu |     |
|     |     | 250 |     |     |     |     | 255 |     |     |     |     | 260 |     |
| ATC | TGC | ATG | AAG | GTC | TTT | GCC | CAG | TAC | ATT | CTG | GGG | GCC | 819 |
| Ile | Cys | Met | Lys | Val | Phe | Ala | Gln | Tyr | Ile | Leu | Gly | Ala |     |
|     |     |     |     | 265 |     |     |     | 270 |     |     |     |     |     |
| GAT | CCT | CTG | AGA | GTC | TGC | TCT | CCT | AGT | GTG | GAT | GAC | CTA | 858 |
| Asp | Pro | Leu | Arg | Val | Cys | Ser | Pro | Ser | Val | Asp | Asp | Leu |     |
|     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |

21

|     |     |     |     |     |     |     |     |     |     |     |     |     |      |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| CGG | GCC | ATC | GCC | GAG | GAG | TCA | GAT | GAG | GAA | GAG | GCT | ATT | 897  |
| Arg | Ala | Ile | Ala | Glu | Glu | Ser | Asp | Glu | Glu | Glu | Ala | Ile |      |
|     |     |     | 290 |     |     |     |     | 295 |     |     |     |     |      |
| GTA | GCC | TAC | ACT | TTG | GCC | ACC | CGT | GGT | GCC | AGC | TCC | TCT | 936  |
| Val | Ala | Tyr | Thr | Leu | Ala | Thr | Arg | Gly | Ala | Ser | Ser | Ser |      |
| 300 |     |     |     |     | 305 |     |     |     |     | 310 |     |     |      |
| GAT | TCT | CTG | GTG | TCA | CCC | CCA | GAG | TCC | CCT | GTA | CCC | GCG | 975  |
| Asp | Ser | Leu | Val | Ser | Pro | Pro | Glu | Ser | Pro | Val | Pro | Ala |      |
|     |     | 315 |     |     |     |     | 320 |     |     |     |     | 325 |      |
| ACT | ATC | CCT | CTG | TCC | TCA | GTA | ATT | GTG | GCT | GAG | AAC | AGT | 1014 |
| Thr | Ile | Pro | Leu | Ser | Ser | Val | Ile | Val | Ala | Glu | Asn | Ser |      |
|     |     |     |     | 330 |     |     |     |     | 335 |     |     |     |      |
| GAT | CAG | GAA | GAA | AGT | GAG | CAG | AGT | GAT | GAG | GAA | GAG | GAG | 1053 |
| Asp | Gln | Glu | Glu | Ser | Glu | Gln | Ser | Asp | Glu | Glu | Glu | Glu |      |
|     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |      |
| GAG | GGT | GCT | CAG | GAG | GAG | CGG | GAG | GAC | ACT | GTG | TCT | GTC | 1092 |
| Glu | Gly | Ala | Gln | Glu | Glu | Arg | Glu | Asp | Thr | Val | Ser | Val |      |
|     |     |     | 355 |     |     |     |     | 360 |     |     |     |     |      |
| AAG | TCT | GAG | CCA | GTG | TCT | GAG | ATA | GAG | GAA | GTT | GCC | CCA | 1131 |
| Lys | Ser | Glu | Pro | Val | Ser | Glu | Ile | Glu | Glu | Val | Ala | Pro |      |
| 365 |     |     |     |     | 370 |     |     |     |     | 375 |     |     |      |
| GAG | GAA | GAG | GAG | GAT | GGT | GCT | GAG | GAA | CCC | ACC | GCC | TCT | 1170 |
| Glu | Glu | Glu | Glu | Asp | Gly | Ala | Glu | Glu | Pro | Thr | Ala | Ser |      |
|     |     | 380 |     |     |     | 385 |     |     |     |     |     | 390 |      |
| GGA | GGC | AAG | AGC | ACC | CAC | CCT | ATG | GTG | ACT | AGA | AGC | AAG | 1209 |
| Gly | Gly | Lys | Ser | Thr | His | Pro | Met | Val | Thr | Arg | Ser | Lys |      |
|     |     |     |     | 395 |     |     |     |     | 400 |     |     |     |      |
| GCT | GAC | CAG | TAA |     |     |     |     |     |     |     |     |     | 1221 |
| Ala | Asp | Gln |     |     |     |     |     |     |     |     |     |     |      |
|     | 405 |     |     |     |     |     |     |     |     |     |     |     |      |

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 406 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

22

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |  |  |  |  |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|--|--|
| Met | Lys | Gln | Ile | Lys | Val | Arg | Val | Asp | Met | Leu | Arg | His | Arg |  |  |  |  |  |  |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     |  |  |  |  |  |  |
| Ile | Lys | Glu | His | Met | Leu | Lys | Lys | Tyr | Thr | Gln | Thr | Glu | Glu |  |  |  |  |  |  |
| 15  |     |     |     |     | 20  |     |     |     |     | 25  |     |     |     |  |  |  |  |  |  |
| Lys | Phe | Thr | Gly | Ala | Phe | Asn | Met | Met | Gly | Gly | Cys | Leu | Gln |  |  |  |  |  |  |
|     | 30  |     |     |     |     | 35  |     |     |     |     | 40  |     |     |  |  |  |  |  |  |
| Asn | Ala | Leu | Asp | Ile | Leu | Asp | Lys | Val | His | Glu | Pro | Phe | Glu |  |  |  |  |  |  |
|     |     | 45  |     |     |     |     | 50  |     |     |     |     | 55  |     |  |  |  |  |  |  |
| Glu | Met | Lys | Cys | Ile | Gly | Leu | Thr | Met | Gln | Ser | Met | Tyr | Glu |  |  |  |  |  |  |
|     |     |     | 60  |     |     |     |     | 65  |     |     |     |     | 70  |  |  |  |  |  |  |
| Asn | Tyr | Ile | Val | Pro | Glu | Asp | Lys | Arg | Glu | Met | Trp | Met | Ala |  |  |  |  |  |  |
|     |     |     |     | 75  |     |     |     |     | 80  |     |     |     |     |  |  |  |  |  |  |
| Cys | Ile | Lys | Glu | Leu | His | Asp | Val | Ser | Lys | Gly | Ala | Ala | Asn |  |  |  |  |  |  |
| 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |     |     |  |  |  |  |  |  |
| Lys | Leu | Gly | Gly | Ala | Leu | Gln | Ala | Lys | Ala | Arg | Ala | Lys | Lys |  |  |  |  |  |  |
|     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |  |  |  |  |  |  |
| Asp | Glu | Leu | Arg | Arg | Lys | Met | Met | Tyr | Met | Cys | Tyr | Arg | Asn |  |  |  |  |  |  |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |  |  |  |  |  |  |
| Ile | Glu | Phe | Phe | Thr | Lys | Asn | Ser | Ala | Phe | Pro | Lys | Thr | Thr |  |  |  |  |  |  |
|     |     |     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |  |  |  |  |  |  |
| Asn | Gly | Cys | Ser | Gln | Ala | Met | Ala | Ala | Leu | Gln | Asn | Leu | Pro |  |  |  |  |  |  |
|     |     |     |     | 145 |     |     |     |     | 150 |     |     |     |     |  |  |  |  |  |  |
| Gln | Cys | Ser | Pro | Asp | Glu | Ile | Met | Ala | Tyr | Ala | Gln | Lys | Ile |  |  |  |  |  |  |
| 155 |     |     |     |     | 160 |     |     |     |     | 165 |     |     |     |  |  |  |  |  |  |
| Phe | Lys | Ile | Leu | Asp | Glu | Glu | Arg | Asp | Lys | Val | Leu | Thr | His |  |  |  |  |  |  |
|     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |     |     |  |  |  |  |  |  |
| Ile | Asp | His | Ile | Phe | Met | Asp | Ile | Leu | Thr | Thr | Cys | Val | Glu |  |  |  |  |  |  |
|     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |     |  |  |  |  |  |  |
| Thr | Met | Cys | Asn | Glu | Tyr | Lys | Val | Thr | Ser | Asp | Ala | Cys | Met |  |  |  |  |  |  |
|     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |  |  |  |  |  |
| Met | Thr | Met | Tyr | Gly | Gly | Ile | Ser | Leu | Leu | Ser | Glu | Phe | Cys |  |  |  |  |  |  |
|     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |  |  |  |  |  |  |



23

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Val | Leu | Ser | Cys | Tyr | Val | Leu | Glu | Glu | Thr | Ser | Val | Met |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |
| Leu | Ala | Lys | Arg | Pro | Leu | Ile | Thr | Lys | Pro | Glu | Val | Ile | Ser |
| 240 |     |     |     |     |     | 245 |     |     |     |     | 250 |     |     |
| Val | Met | Lys | Arg | Arg | Ile | Glu | Glu | Ile | Cys | Met | Lys | Val | Phe |
|     |     | 255 |     |     |     |     | 260 |     |     |     |     | 265 |     |
| Ala | Gln | Tyr | Ile | Leu | Gly | Ala | Asp | Pro | Leu | Arg | Val | Cys | Ser |
|     |     |     | 270 |     |     |     |     | 275 |     |     |     |     | 280 |
| Pro | Ser | Val | Asp | Asp | Leu | Arg | Ala | Ile | Ala | Glu | Glu | Ser | Asp |
|     |     |     |     | 285 |     |     |     |     | 290 |     |     |     |     |
| Glu | Glu | Glu | Ala | Ile | Val | Ala | Tyr | Thr | Leu | Ala | Thr | Arg | Gly |
| 295 |     |     |     |     | 300 |     |     |     |     | 305 |     |     |     |
| Ala | Ser | Ser | Ser | Asp | Ser | Leu | Val | Ser | Pro | Pro | Glu | Ser | Pro |
|     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |     |     |
| Val | Pro | Ala | Thr | Ile | Pro | Leu | Ser | Ser | Val | Ile | Val | Ala | Glu |
|     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |
| Asn | Ser | Asp | Gln | Glu | Glu | Ser | Glu | Gln | Ser | Asp | Glu | Glu | Glu |
|     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |
| Glu | Glu | Gly | Ala | Gln | Glu | Glu | Arg | Glu | Asp | Thr | Val | Ser | Val |
|     |     |     |     | 355 |     |     |     |     | 360 |     |     |     |     |
| Lys | Ser | Glu | Pro | Val | Ser | Glu | Ile | Glu | Glu | Val | Ala | Pro | Glu |
| 365 |     |     |     |     | 370 |     |     |     |     | 375 |     |     |     |
| Glu | Glu | Glu | Asp | Gly | Ala | Glu | Glu | Pro | Thr | Ala | Ser | Gly | Gly |
|     | 380 |     |     |     |     | 385 |     |     |     |     | 390 |     |     |
| Lys | Ser | Thr | His | Pro | Met | Val | Thr | Arg | Ser | Lys | Ala | Asp | Gln |
|     |     | 395 |     |     |     |     | 400 |     |     |     |     | 405 |     |

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTATCCTCCT CTAGAATGAA ACAGATTAAG

30

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATATATATAT TCTAGAGTTT ACTGGTCGAC

30

## WHAT IS CLAIMED IS:

1. A non-defective recombinant adenovirus comprising a cytomegalovirus gene encoding an immediate early antigen exon-4 subunit protein from a human strain of cytomegalovirus, said gene being under the control of an expression control sequence, said virus being a type 5 strain adenovirus capable of expressing said subunit protein in vivo in an animal.
2. The non-defective recombinant adenovirus according to claim 1, wherein the human cytomegalovirus strain is Towne.
3. An immunogenic composition comprising a non-defective recombinant adenovirus comprising a cytomegalovirus gene encoding an immediate early antigen exon-4 subunit protein from a human strain of cytomegalovirus, said gene being under the control of an expression control sequence, said virus being a type 5 strain adenovirus capable of expressing said subunit protein in vivo in an animal, in a suitable pharmaceutical carrier.
4. The composition according to claim 3, wherein the human cytomegalovirus is Towne strain.
5. A human cytomegalovirus immediate early exon-4 subunit protein produced by an adenovirus expression vector.

6. The use of a non-defective recombinant adenovirus comprising a cytomegalovirus gene encoding an immediate early antigen exon-4 subunit protein from a human strain of cytomegalovirus, said gene being under the control of an expression control sequence, said virus being a type 5 strain adenovirus capable of expressing said subunit protein in vivo in an animal, in admixture with a suitable pharmaceutical carrier in the manufacture of a vaccine composition against cytomegalovirus infection.

7. The use according to claim 6 wherein said vaccine is manufactured for oral administration.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/07107

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : Please See Extra Sheet.

US CL : 424/88, 89; 435/235.1, 69.3, 69.1, 5, 172.3; 436/546; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/88, 89; 435/235.1, 69.3, 69.1, 5, 172.3; 436/546; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

INTELLIGENETICS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
| Y         | US, A, 4,920,209 (DAVIS ET AL.) 24 April 1990, See entire document.  | 1-7                   |
| Y         | The EMBO Journal, Volume 5, Number 11, issued November 1986, M.P. Cranage et al., "Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus", pages 3057-3063, See entire document. | 1-7                   |
| Y         | Journal of Virology, Volume 65, Number 9, issued September 1991, N.J. Alp et al., "Fine Specificity of Cellular Immune Responses in Humans to Human cytomegalovirus Immediate-Early 1 Protein", pages 4812-4820, see entire document.  | 1-7                   |



Further documents are listed in the continuation of Box C.



See patent family annex.

°

Special categories of cited documents

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention

\*A\*

document defining the general state of the art which is not considered to be part of particular references

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*E\*

earlier document published on or after the international filing date

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is considered with one or more other such documents, such combination being obvious to a person skilled in the art

\*L\*

document which may have priority claim(s) or which is cited to establish the publication date of another citation or other special reason (to be specified)

Y

\*O\*

document referring to an art disclosure, viz. exhibition or other means

A

document member of the same patent family

\*P\*

document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

Date of mailing of the international search report

03 JUNE 1994

JUN 24 1994

Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box FCT  
 Washington, D.C. 20231

Authorized officer

LAURIE SCHEINER

S. Kuzza

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/ISA/210

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

A61K 31/70, 39/12; C12N 7/00, 15/00; C12P 21/06; C12Q 1/70; G01N 33/531